Promoting Pioneering Research
There is an urgent need for specific research efforts to develop an early detection protocol that will significantly improve survival for those diagnosed with pancreatic cancer. We are committed to promoting pioneering initiatives which demonstrate valuable potential for achieving this goal.
Innovation leading to significant advances in research and subsequent translation to clinical practice is urgently necessary in early detection of sporadic pancreatic cancer. The white paper, Early Detection of Sporadic Pancreatic Cancer: Strategic Map for Innovation, was published in May 2015 to report on the outcomes derived from the Early Detection of Sporadic Pancreatic Cancer Summit Conference conducted in November 2014. Responding to the dearth of any recent significant advancements in early detection, this summit brought together international interdisciplinary scientific representatives who engaged in strategic facilitated conversations to formulate a defined future for this field.
Ideas generated from the summit led to the design of a Strategic Map for Innovation built upon three components: formation of an international collaborative effort; design of an actionable strategic plan; and implementation of operational standards, research priorities, and first phase initiatives.Through the committed efforts of leading researchers and institutions, philanthropic partners, government agencies and supportive business entities this endeavor will lead to future changes within the field and consequently impact the survival rate of those diagnosed with pancreatic cancer.
“A collaborative investment in research and translation into clinical practice is the only way that we will advance this field. We must work together to design a new strategic map through the sharing of knowledge, technology, resources, and commitment. The Early Detection of Sporadic Pancreatic Cancer Summit Conference was the first ever convening of an international body of experts to directly address the need for a new approach. I am confident that as a result of this summit we will develop an early detection protocol to help individuals who are diagnosed with this disease.” - Vay Liang W. (Bill) Go, MD Dr. Go is a distinguished professor and the Co-Director of the UCLA Agi Hirshberg Center for Pancreatic Diseases at the David Geffen School of Medicine at UCLA. He is also the editor in chief of the journal Pancreas and co-founder of the American Pancreatic Association and the UCLA Center for Human Nutrition. His research has focused on investigating pancreatitis, pancreatic cancer, diabetes mellitus and metabolic diseases. Dr. Go also serves as a member of the Kenner Family Research Fund Scientific Advisory Board.